^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    BCOR (BCL6 Corepressor)

    i
    Other names: BCOR, BCL6 Corepressor, BCL6 Interacting Corepressor, BCL-6 Corepressor, BCL-6 Coreceptor, BCL-6 Interacting Corepressor, BCL6 Co-Repressor, FLJ20285, MCOPS2, ANOP2
    5d
    Small Round Cell Tumors of Soft Tissue and Skeleton in Children and Youth: A Narrative and TruSight-Based Illustrative Review of Diagnostic Cases. (PubMed, Adv Anat Pathol)
    Immunohistochemistry plays a crucial role in interpreting a specific diagnosis or narrowing the differential diagnosis of SRCTs. Molecular genetic investigations are essential, particularly in cases exhibiting atypical or overlapping histologic and immunohistological features.
    Journal
    |
    BCOR (BCL6 Corepressor) • EWSR1 (EWS RNA Binding Protein 1)
    7d
    Azacitidine-induced remission enables allogeneic transplantation in TET2/BCOR-mutant relapsed extranodal natural killer/T-cell lymphoma: a case report. (PubMed, Haematologica)
    Not available.
    Journal
    |
    TET2 (Tet Methylcytosine Dioxygenase 2) • BCOR (BCL6 Corepressor)
    |
    TET2 mutation
    |
    azacitidine
    8d
    Undifferentiated Round Cell Sarcomas: A Comprehensive Review and Practical Diagnostic Guide with an Emphasis on Superficial Body Sites. (PubMed, Int J Surg Pathol)
    We highlight an integrated diagnostic framework that combines morphology, broad immunohistochemical panels, and molecular testing. Accurate recognition of these tumors is essential, as correct classification directly informs prognosis and therapeutic decision-making.
    Review • Journal
    |
    BCOR (BCL6 Corepressor) • EWSR1 (EWS RNA Binding Protein 1)
    9d
    Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Peking University People's Hospital
    New trial • Tumor mutational burden • Minimal residual disease
    |
    ABL1 (ABL proto-oncogene 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1) • HOXA9 (Homeobox A9) • NUP214 (Nucleoporin 214) • FUS (FUS RNA Binding Protein) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    NPM1 mutation • MLL rearrangement
    13d
    Undifferentiated Small Round Cell Sarcomas: Radiologic-Pathologic Correlation for the Updated WHO Classification Fifth Edition (2020). (PubMed, Radiographics)
    The authors provide an overview of the clinical features, pathologic findings, imaging characteristics, differential diagnosis, and treatment outcomes of each entity.
    Review • Journal
    |
    BCOR (BCL6 Corepressor) • EWSR1 (EWS RNA Binding Protein 1)
    14d
    Revumenib in Combination With 7+3 + Midostaurin in AML (clinicaltrials.gov)
    P1, N=22, Recruiting, Richard Stone, MD | Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • SRSF2 (Serine and arginine rich splicing factor 2) • CREBBP (CREB binding protein) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • MECOM (MDS1 And EVI1 Complex Locus) • NUP214 (Nucleoporin 214) • GATA2 (GATA Binding Protein 2) • KAT6A (Lysine Acetyltransferase 6A) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    TP53 mutation • FLT3-ITD mutation • NPM1 mutation • Chr del(5q)
    |
    midostaurin • daunorubicin • Revuforj (revumenib)
    15d
    Comprehensive assessment of the genomic stability of human induced pluripotent stem cells for clinical applications. (PubMed, Stem Cell Res Ther)
    This study established a comprehensive strategy for evaluating the genomic alterations of hiPSCs by integrating karyotyping, OGM, WES, and RNA-seq. This comprehensive strategy can be applied to scenarios such as hiPSC clone screening, establishment of cell bank passages, and quality control of hiPSC-derived products. It provides a reliable genetic stability evaluation protocol to support the safe clinical application of hiPSC-related products.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BCL2L1 (BCL2-like 1) • CDH1 (Cadherin 1) • BCOR (BCL6 Corepressor)
    23d
    GFH009X2101: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML (clinicaltrials.gov)
    P1/2, N=160, Recruiting, Sellas Life Sciences Group | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • DDX41 (DEAD-Box Helicase 41) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    TP53 mutation • KRAS mutation • FLT3-ITD mutation • Chr del(17p) • IDH1 mutation • IDH2 mutation • FLT3 mutation • TP53 wild-type • NPM1 mutation • KRAS wild-type • Chr del(11q) • ASXL1 mutation • SF3B1 mutation • EZH2 mutation • NRAS wild-type • SRSF2 mutation • IDH wild-type
    |
    Venclexta (venetoclax) • azacitidine • tambiciclib (SLS009)
    1m
    Prognostic impact of myelodysplasia-related gene mutations in ELN-2022 favorable-risk acute myeloid leukemia subtypes. (PubMed, Ann Med)
    The presence of a single MRG mutation did not confer a worse prognosis in favorable-risk AML, whereas a high MRG mutation burden (≥2 mutations) was independently associated with poorer LFS. This study suggests that quantifying the MRG mutation burden may inform risk stratification in this patient population.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • ETV6 (ETS Variant Transcription Factor 6) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    TMB-H • ASXL1 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation
    1m
    Epigenetic corepressor BCORL1 predominates as a driver of clonal hematopoiesis of indeterminate potential in patients undergoing chronic hemodialysis: a multicenter cohort study. (PubMed, Hum Genomics)
    CHIP in Asian patients undergoing chronic hemodialysis shows a high prevalence and a distinct mutation spectrum dominated by BCORL1. These findings suggest disease- and ancestry-specific selective pressures beyond aging and support gene-specific risk stratification and closer hematologic surveillance. Further multi-ethnic studies are needed to define the cardiovascular and hematologic implications of BCORL1-associated CHIP.
    Journal
    |
    DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • BCOR (BCL6 Corepressor) • GNAS (GNAS Complex Locus) • BCORL1 (BCL6 Corepressor Like 1)
    1m
    A Rapidly Growing Cervical Tumor in an Infant: Sarcoma with BCOR Gene Alterations. (PubMed, Int J Surg Pathol)
    At six-month follow-up, the patient remained clinically stable, with no evidence of local recurrence or distant metastasis. This patient's presentation underscores the essential role of comprehensive genomic profiling in distinguishing between histologically similar pediatric sarcomas and guiding appropriate, individualized treatment.
    Journal
    |
    BCL6 (B-cell CLL/lymphoma 6) • BCOR (BCL6 Corepressor)
    1m
    Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis. (PubMed, Haematologica)
    Among the patients with ELN-2022 intermediate risk (n=1,294), 108 (8.3%) had MRG mutations. The presence of MRG mutations was significantly associated with inferior overall survival (pooled hazard ratio [HR] 1.30; 95% confidence interval [CI], 1.11-1.51; p.
    Retrospective data • Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    NPM1 mutation